Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Chengbao Ma"'
Publikováno v:
Cell Insight, Vol 3, Iss 1, Pp 100145- (2024)
Angiotensin-converting enzyme 2 (ACE2) was recognized as an entry receptor shared by coronaviruses from Sarbecovirus and Setracovirus subgenera, including three human coronaviruses: SARS-CoV, SARS-CoV-2, and NL63. We recently disclosed that NeoCoV an
Externí odkaz:
https://doaj.org/article/4d75d162c2dd46efaef8a47917898578
Autor:
Chengbao Ma, Chen Liu, Qing Xiong, Mengxue Gu, Lulu Shi, Chunli Wang, Junyu Si, Fei Tong, Peng Liu, Meiling Huang, Huan Yan
Publikováno v:
Cell Discovery, Vol 9, Iss 1, Pp 1-16 (2023)
Abstract Recently, two Middle East respiratory syndrome coronavirus (MERS-CoV) closely related to bat merbecoviruses, NeoCoV and PDF-2180, were discovered to use angiotensin-converting enzyme 2 (ACE2) for entry. The two viruses cannot use human ACE2
Externí odkaz:
https://doaj.org/article/fb7799be5e22470bbf2591d9d896f099
Autor:
Jiangpeng Feng, Tianmo Xu, Miao He, Jiali Li, Peipei Yao, Chengbao Ma, Shimin Yang, Zaichao Xu, Kun Yan, Xianying Chen, Hongyun Wang, Jiejie Liu, Cong Zeng, Yuchen Xia, Huan Yan, Li Zhou, Yu Chen
Publikováno v:
PLoS Pathogens, Vol 19, Iss 12, p e1011808 (2023)
Chronic hepatitis B virus (HBV) infection is a major cause of liver cirrhosis and liver cancer, despite strong prevention and treatment efforts. The study of the epigenetic modification of HBV has become a research hotspot, including the N6-methylade
Externí odkaz:
https://doaj.org/article/ea7c1523e5484e04856cc13752e57426
Autor:
Chengbao Ma, Xianying Chen, Fanghua Mei, Qing Xiong, Qianyun Liu, Lianghui Dong, Chen Liu, Wenjing Zou, Faxian Zhan, Bing Hu, Yingle Liu, Fang Liu, Li Zhou, Junqiang Xu, Yongzhong Jiang, Ke Xu, Kun Cai, Yu Chen, Huan Yan, Ke Lan
Publikováno v:
Emerging Microbes and Infections, Vol 11, Iss 1, Pp 567-572 (2022)
Global concern has been raised by the emergence and rapid transmission of the heavily mutated SARS-CoV-2 Omicron variant (B.1.1.529). So far, the infection features and immune escape ability of the Omicron variant have not been extensively studied. H
Externí odkaz:
https://doaj.org/article/f79fddb058334f33985e226298695c48
Autor:
Qianyun Liu, Qing Xiong, Fanghua Mei, Chengbao Ma, Zhen Zhang, Bing Hu, Junqiang Xu, Yongzhong Jiang, Faxian Zhan, Suhua Zhou, Li Tao, Xianying Chen, Ming Guo, Xin Wang, Yaohui Fang, Shu Shen, Yingle Liu, Fang Liu, Li Zhou, Ke Xu, Changwen Ke, Fei Deng, Kun Cai, Huan Yan, Yu Chen, Ke Lan
Publikováno v:
The Innovation, Vol 3, Iss 1, Pp 100181- (2022)
Most COVID-19 convalescents can build effective anti-SARS-CoV-2 humoral immunity, but it remains unclear how long it can maintain and how efficiently it can prevent the reinfection of the emerging SARS-CoV-2 variants. Here, we tested the sera from 24
Externí odkaz:
https://doaj.org/article/1b86bffd4295484e8c86ee9a5d452e51
Autor:
Qing Xiong, Lei Cao, Chengbao Ma, M. Alejandra Tortorici, Chen Liu, Junyu Si, Peng Liu, Mengxue Gu, Alexandra C. Walls, Chunli Wang, Lulu Shi, Fei Tong, Meiling Huang, Jing Li, Chufeng Zhao, Chao Shen, Yu Chen, Huabin Zhao, Ke Lan, Davide Corti, David Veesler, Xiangxi Wang, Huan Yan
Publikováno v:
Nature. 612:748-757
Middle East respiratory syndrome coronavirus (MERS-CoV) and several bat coronaviruses use dipeptidyl peptidase-4 (DPP4) as an entry receptor1–4. However, the receptor for NeoCoV—the closest known MERS-CoV relative found in bats—remains unclear5
Autor:
Chengbao Ma, Chen Liu, Qing Xiong, Mengxue Gu, Lulu Shi, Chunli Wang, Junyu Si, Fei Tong, Peng Liu, Meiling Huang, Huan Yan
SummaryPhylogenetically distant coronaviruses have evolved to use ACE2 as their common receptors, including NL63 and many Severe acute respiratory syndrome (SARS) coronavirus-related viruses. We recently reported two Middle East respiratory syndrome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fcb3442fb397a9af28cd79f3f7120d5
https://doi.org/10.1101/2022.09.11.507506
https://doi.org/10.1101/2022.09.11.507506
Autor:
Ke Xu, Bing Hu, Shu Shen, Faxian Zhan, Xin Wang, Qianyun Liu, Yaohui Fang, Suhua Zhou, Yongzhong Jiang, Huan Yan, Ming Guo, Fei Deng, Yu Chen, Qing Xiong, Li Tao, Yingle Liu, Kun Cai, Li Zhou, Junqiang Xu, Zhen Zhang, Xianying Chen, Fanghua Mei, Chengbao Ma, Changwen Ke, Fang Liu, Ke Lan
Publikováno v:
The Innovation
The Innovation, Vol 3, Iss 1, Pp 100181-(2022)
The Innovation, Vol 3, Iss 1, Pp 100181-(2022)
Most COVID-19 convalescents can build effective anti-SARS-CoV-2 humoral immunity, but it remains unclear how long it can maintain and how efficiently it can prevent the reinfection of the emerging SARS-CoV-2 variants. Here, we tested the sera from 24
Autor:
Qing Xiong, Chengbao Ma, Bing Hu, Yingle Liu, Kun Cai, Zhen Zhang, Huan Yan, Qianyun Liu, Yongzhong Jiang, Faxian Zhan, Xianying Chen, Fang Liu, Ming Guo, Fanghua Mei, Changwen Ke, Shu Shen, Ke Lan, Xin Wang, Li Zhou, Fei Deng, Yu Chen, Junqiang Xu, Yaohui Fang, Ke Xu
Most COVID-19 patients can build effective humoral immunity against SARS-CoV-2 after recovery(1, 2). However, it remains unknown how long the protection can maintain and how efficiently it can protect people from the reinfection of the emerging SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcf96790190f73360931178f33c2b36c
https://doi.org/10.1101/2021.06.16.21258673
https://doi.org/10.1101/2021.06.16.21258673